Bronte Capital Management Pty Ltd. Buys 33,177 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Bronte Capital Management Pty Ltd. lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 187,870 shares of the biopharmaceutical company’s stock after acquiring an additional 33,177 shares during the period. Regeneron Pharmaceuticals accounts for about 20.8% of Bronte Capital Management Pty Ltd.’s investment portfolio, making the stock its 2nd largest position. Bronte Capital Management Pty Ltd. owned approximately 0.18% of Regeneron Pharmaceuticals worth $98,632,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. PGGM Investments lifted its position in Regeneron Pharmaceuticals by 159.7% during the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock worth $44,308,000 after acquiring an additional 51,900 shares during the last quarter. Founders Capital Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 7.0% during the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock worth $4,344,000 after purchasing an additional 538 shares during the last quarter. Sepio Capital LP boosted its stake in Regeneron Pharmaceuticals by 33.1% during the 1st quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock valued at $2,150,000 after purchasing an additional 842 shares during the period. Generate Investment Management Ltd bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $6,300,000. Finally, Bellecapital International Ltd. grew its holdings in Regeneron Pharmaceuticals by 32.7% in the 2nd quarter. Bellecapital International Ltd. now owns 25,503 shares of the biopharmaceutical company’s stock valued at $13,389,000 after buying an additional 6,283 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on REGN shares. Bank of America upped their price target on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the stock an “underperform” rating in a report on Wednesday, October 29th. Guggenheim upped their target price on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. UBS Group increased their price target on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Citigroup boosted their price objective on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $772.76.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Trading Down 3.1%

Shares of REGN stock opened at $702.75 on Thursday. The firm has a fifty day moving average of $608.00 and a 200-day moving average of $573.41. The stock has a market cap of $73.86 billion, a price-to-earnings ratio of 16.83, a P/E/G ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $800.99. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter in the previous year, the firm posted $12.46 earnings per share. The firm’s revenue for the quarter was up .9% on a year-over-year basis. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.43%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.